Skip to main content
Transgene logo

Transgene — Investor Relations & Filings

Ticker · TNG ISIN · FR0005175080 LEI · 969500PDJW8N0FSGGK69 PA Professional, scientific and technical activities
Open in API
Filings indexed 796 across all filing types
Latest filing 2010-10-18 Interim / Quarterly Rep…
Country FR France
Listing PA TNG

About Transgene

https://www.transgene.fr/en/

Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.

Recent filings

Filing Released Lang Actions
Transgene: Third Quarter 2010 Financial report
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Third Quarter 2010 Financial Report' and contains specific financial data, including revenue tables for Q3 and the first nine months of 2010, as well as cash position analysis. It provides a comprehensive overview of the company's financial performance for the interim period. It is not a mere announcement (RPA) as it contains substantive financial tables and analysis. Therefore, it is classified as an Interim/Quarterly Report. 9M 2010
2010-10-18 English
Transgene signe un accord avec Ventana Medical Systems, Inc. pour le développement d'un test de diagnostic associé pour le produit TG4010 de Transgene
Regulatory Filings Classification · 1% confidence The document is a press release dated September 29, 2010, announcing a collaboration agreement between Transgene and Ventana Medical Systems for the development of a companion diagnostic test (IHC) for Transgene's product TG4010. This announcement details a strategic partnership, product development plans (including clinical trial phases), and future regulatory steps (AMM/PMA). This content is characteristic of a corporate announcement regarding business development, partnerships, or strategic updates, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it describes a significant business arrangement and development strategy, it fits best under a general corporate/business update category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release announcing a strategic deal that doesn't fit the more specific categories like M&A (TAR) or Financing (CAP). However, since the core topic is a strategic partnership and development plan, and there isn't a specific 'Partnership Announcement' code, RNS serves as the best fit among the provided choices for a non-standard, material corporate news release.
2010-09-29 French
TRANSGENE : Transgene signs an agreement with Ventana Medical Systems, Inc. to develop a companion diagnostic test for Transgene's TG4010
Regulatory Filings Classification · 1% confidence The document is a press release dated September 29, 2010, announcing a collaboration agreement between Transgene and Ventana Medical Systems to develop a companion diagnostic test for Transgene's TG4010 immunotherapy product. It details the clinical trial plans (Phase IIb/III), regulatory pathways (NDA, PMA), and provides background information on the product, the disease (NSCLC), and the companies involved. This type of announcement, detailing a strategic partnership, clinical development milestones, and future regulatory steps, is characteristic of a general corporate announcement or news release, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a significant corporate event announcement that doesn't fit the highly specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate classification is the general Regulatory Filings/Announcements category, RNS, which serves as a broad category for significant, non-standard corporate news releases.
2010-09-29 English
Transgene : communiqué de mise à disposition du rapport financier semestriel au 30 juin 2010
Report Publication Announcement Classification · 1% confidence The document is a short announcement (739 characters) stating that the company has made its semi-annual financial report available to the public and filed it with the Autorité des marchés financiers. It provides a link to the website for consultation rather than containing the actual financial statements or data. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA). H1 2010
2010-09-27 French
TRANSGENE : RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2010
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2010' (Semi-annual Financial Report as of June 30, 2010). It contains comprehensive financial statements including the consolidated balance sheet, income statement, cash flow statement, and statement of changes in equity for the six-month period. It is not an announcement or a summary, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2010
2010-09-27 French
TRANSGENE : RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2010
Interim / Quarterly Report Classification · 1% confidence The document is a 'Rapport Financier Semestriel' (Interim Financial Report) for the period ending June 30, 2010. It contains comprehensive financial statements including the consolidated balance sheet, income statement, cash flow statement, and statement of changes in equity. It is not an announcement or a summary, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2010
2010-09-27 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.